Advances in Therapy

, Volume 25, Issue 9, pp 894–913 | Cite as

LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

  • Kenneth Blum
  • Amanda L. C. Chen
  • Thomas J. H. Chen
  • Patrick Rhoades
  • Thomas J. Prihoda
  • B. William Downs
  • Roger L. Waite
  • Lonna Williams
  • Eric R. Braverman
  • Dasha Braverman
  • Vanessa Arcuri
  • Mallory Kerner
  • Seth H. Blum
  • Tomas Palomo
Original Research



This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen®, Inc., La Jolla, CA, USA).


A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed.


Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-γ2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045).


If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.


LG839 neurotransmitters obesity reward deficiency syndrome sugar craving behavior weight loss 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Institute of Medicine. Weighting the Options: Criteria for Evaluating Weight Management Programs. Washington DC: National Academy Press; 1995.Google Scholar
  2. 2.
    National Institutes of Health, National Heart, Lung and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. NIH Publication No. 98-4083. Bethesda, MD: NIH; 1998.Google Scholar
  3. 3.
    World Health Organization. International Classification of Diseases, Ninth Revision, Clinical Modification. Geneva: WHO; 1975. Available at: Accessed July 2008.Google Scholar
  4. 4.
    US Food and Drug Administration, Department of Health and Human Services. Final Rules: Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body. Effective February 7, 2000. FDA Docket No. 98N-0044. Rockville, MD: FDA; 2000;65.Google Scholar
  5. 5.
    Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1996;276:1907–1915.Google Scholar
  6. 6.
    U.S. Census Bureau web site. Available at: Accessed July 2008.Google Scholar
  7. 7.
    Stobbe M. Survey: most obese claim to eat healthy. LiveScience web site. Available at: August 15, 2006. Accessed July 2008.Google Scholar
  8. 8.
    Blum K, Chen TJ, Meshkin B, et al. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses. 2007;68:844–852.PubMedCrossRefGoogle Scholar
  9. 9.
    Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA. 1990;263:2055–2060.PubMedCrossRefGoogle Scholar
  10. 10.
    Blum K, Braverman ER, Wood RC, et al. Increased prevalence of the TaqI A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics. 1996;6:297–305.PubMedCrossRefGoogle Scholar
  11. 11.
    Blum K, Kozlowski GP. Ethanol and neuromodulator interactions: a cascade model of reward. In: Ollat H, Parvez S, Parvez H, eds. Alcohol and Behavior. Utrecht: VSP Press; 1990:131–149.Google Scholar
  12. 12.
    Blum K, Cull JG, Braverman ER, et al. Reward deficiency syndrome. Am Sci. 1996;84:132–145.Google Scholar
  13. 13.
    Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996;89:396–400.PubMedGoogle Scholar
  14. 14.
    Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res. 2000;126:325–341.PubMedCrossRefGoogle Scholar
  15. 15.
    Nomura M, Nomura Y. Psychological, neuroimaging, and biochemical studies on functional association between impulsive behavior and the 5-HT2A receptor gene polymorphism in humans. Ann N Y Acad Sci. 2006;1086:134–143.PubMedCrossRefGoogle Scholar
  16. 16.
    Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviors. J Psychoactive Drugs. 2000;32(suppl. 1–4):1–112.Google Scholar
  17. 17.
    Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:29–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Di Renzo L, Bigioni M, Bottini FG, et al. Normal weight obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C— >T genes in the relationship between body composition and resting metabolic rate. Eur Rev Med Pharmacol Sci. 2006;10:235–245.PubMedGoogle Scholar
  19. 19.
    Rance KA, Johnstone AM, Murison S, Duncan JS, Wood SG, Speakman JR. Plasma leptin levels are related to body composition, sex, insulin levels and the A55V polymorphism of the UCP2 gene. Int J Obes (Lond). 2007;31:1311–1318.CrossRefGoogle Scholar
  20. 20.
    Nonogaki K, Nozue K, Oka Y. Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice. Biochem Biophys Res Commun. 2006;351:1078–1082.PubMedCrossRefGoogle Scholar
  21. 21.
    Fang YJ, Thomas GN, Xu ZL, Fang JQ, Critchley JA, Tomlinson B. An affected pedigree member analysis of linkage between the dopamine D2 receptor gene TaqI polymorphism and obesity and hypertension. Int J Cardiol. 2005;102:111–116.PubMedCrossRefGoogle Scholar
  22. 22.
    Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507–514.PubMedCrossRefGoogle Scholar
  23. 23.
    Rosmond R, Chagnon M, Bouchard C. The Pro12Ala PPARgamma2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab Res Rev. 2003;19:159–163.PubMedCrossRefGoogle Scholar
  24. 24.
    Blum K, Trachtenberg MC, Cook DW. Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. Curr Ther Res. 1990;48:217–233.Google Scholar
  25. 25.
    Blum K, Cull JG, Chen TJH, et al. Clinical evidence for Phencal in maintaining weight loss in an open-label, controlled 2-year study. Curr Ther Res. 1997;58:745–763.CrossRefGoogle Scholar
  26. 26.
    Blum K, Chen TJ, Meshkin B, et al. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther. 2006;23:1040–1051.PubMedCrossRefGoogle Scholar
  27. 27.
    Comings DE, Gade R, MacMurray JP, Muhleman D, Peters WR. Genetic variants of the human obesity (OB) gene: association with psychiatric symptoms and body mass index in young women, and interaction with the dopamine D2 receptor (DRD2) gene. Mol Psychiatry. 1996;1:325–335.PubMedGoogle Scholar
  28. 28.
    Green ED, Maffei M, Braden VV, et al. The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Genome Res. 1995;5:5–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Comings DE. Polygenic inheritance and minisatellites. Psychiat Genet. 1996;6:157–158.CrossRefGoogle Scholar
  30. 30.
    Gade R, Muhleman D, Blake H, et al. Correlation of length of VNTR alleles at the X-linked MAOA gene and phenotypic effect in Tourette syndrome and drug abuse. Mol Psychiatry. 1998;3:50–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Russo GT, Di Benedetto A, Alessi E, et al. Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in type 2 diabetes. J Endocrinol Invest. 2006;29:201–207.PubMedGoogle Scholar
  32. 32.
    Thawnashom K, Tungtrongchitr R, Petmitr S, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) in relation to homocysteine concentration in overweight and obese Thais. Southeast Asian J Trop Med Public Health. 2005;36:459–466.PubMedGoogle Scholar
  33. 33.
    Sheu WH, Chin HM, Lee WJ, et al. Prospective evaluation of folic acid supplementation on plasma homocysteine concentrations during weight reduction: a randomized, double-blinded, placebo-controlled study in obese women. Life Sci. 2005;76:2137–2145.PubMedCrossRefGoogle Scholar
  34. 34.
    Thom E. Hydroxycitrate (HCA) in the treatment of obesity. Int J Obes. 1996;20:75.Google Scholar
  35. 35.
    Preuss HG, Bagchi D, Bagchi M, et al. Efficacy of a novel, natural extract of (−)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX, niacin bound chromium and gymnema sylvestre extract in weight management in human volunteers: a pilot study. Nutr Res. 2004;24:45–58.CrossRefGoogle Scholar
  36. 36.
    Chen TJ, Blum K, Payte JT, et al. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses. 2004;63:538–548.PubMedCrossRefGoogle Scholar
  37. 37.
    Milner JD, Irie K, Wurtman RJ. Effect of phenylalanine on the release of endogenous dopamine from rat striatal slices. J Neurochem. 1986;47:1444–1448.PubMedCrossRefGoogle Scholar
  38. 38.
    Volek JS, Gomez AL, Love DM, et al. Effects of an 8-week weight-loss program on cardiovascular disease risk factors and regional body composition. Eur J Clin Nutr. 2002;56:585–592.PubMedCrossRefGoogle Scholar
  39. 39.
    Fisher LD, van Belle G. Biostatistics: a Methodology for the Health Sciences. New York: Wiley; 1993.Google Scholar
  40. 40.
    Food and Drug Administration Center For Drug Evaluation and Research (CDER). Joint Meeting of the Nonprescription Drugs and the Endocrinologic & Metabolic Drugs Advisory Committee. January 23, 2006. Available at: Accessed July 2008.Google Scholar
  41. 41.
    Maes HH, Neale MC, Eaves IJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27:325–351.PubMedCrossRefGoogle Scholar
  42. 42.
    Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354–357.PubMedCrossRefGoogle Scholar
  43. 43.
    Ostergard T, Ek J, Hamid Y, et al. Influence of the PPAR-gamma2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects. Horm Metab Res. 2005;37:99–105.PubMedCrossRefGoogle Scholar
  44. 44.
    Stumvoll M, Haring H. The peroxisome proliferator-activated receptor gamma2 Pro12Ala polymorphism. Diabetes. 2002;51:2341–2347.PubMedCrossRefGoogle Scholar
  45. 45.
    Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284–287.PubMedCrossRefGoogle Scholar
  46. 46.
    Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Koch M, Rett K, Maerker E, et al. The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia. 1999;42: 758–762.PubMedCrossRefGoogle Scholar
  48. 48.
    Adamo KB, Sigal RJ, Williams K, Kenny G, Prud’homme D, Tesson F. Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. Diabetologia. 2005;48:1503–1509.PubMedCrossRefGoogle Scholar
  49. 49.
    Tozzi F, Bulik CM. Candidate genes in eating disorders. Curr Drug Targets CNS Neurol Disord. 2003;2:31–39.PubMedCrossRefGoogle Scholar
  50. 50.
    Tataranni PA, Baier L, Jenkinson C, et al. A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Diabetes. 2001;50:901–904.PubMedCrossRefGoogle Scholar
  51. 51.
    Wainer H. The most dangerous equation. Am Sci. 2007;95:249–256.Google Scholar

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  • Kenneth Blum
    • 1
    • 2
    • 3
    • 4
    • 11
  • Amanda L. C. Chen
    • 5
    • 6
  • Thomas J. H. Chen
    • 5
    • 6
  • Patrick Rhoades
    • 7
  • Thomas J. Prihoda
    • 8
  • B. William Downs
    • 2
  • Roger L. Waite
    • 2
  • Lonna Williams
    • 2
  • Eric R. Braverman
    • 9
    • 3
  • Dasha Braverman
    • 3
  • Vanessa Arcuri
    • 3
  • Mallory Kerner
    • 3
  • Seth H. Blum
    • 4
  • Tomas Palomo
    • 10
  1. 1.Department of Physiology & PharmacologyWake Forest University School of MedicineWinston-SalemUSA
  2. 2.LifeGen®, Inc.La JollaUSA
  3. 3.PATH Medical & Research FoundationNew YorkUSA
  4. 4.Synaptamine™, Inc.San AntonioUSA
  5. 5.Chang Jung Christian UniversityTainanTaiwan
  6. 6.Changhua Christian HospitalChanghuaTaiwan
  7. 7.Comprehensive Obesity ClinicModestoUSA
  8. 8.Department of PathologyUniversity of Texas Health Science CenterSan AntonioUSA
  9. 9.Department of NeurosurgeryWeill Cornell Medical CollegeNew YorkUSA
  10. 10.Hospital UniversitarioMadridSpain
  11. 11.Department of Physiology & PharmacologyWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations